Please assess the completion status of the following clinical trial:

Trial Title: Long Term Open Label Continuation Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Participant was in a prior D2E7 (adalimumab) study~* Participant was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.~Exclusion Criteria~* Participant was considered by the investigator, for any reason, to be an unsuitable candidate for the study~* Participant was a female subject who is pregnant or breast-feeding or considering becoming pregnant~* Participant had any ongoing chronic or active infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: EXPERIMENTAL): Open-label adalimumab 40 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).